Medpace Holdings Inc vs Workiva Inc — how do they compare? Medpace Holdings Inc trades at $599.22 (market cap $16.90B), while Workiva Inc trades at $67.87 (market cap $3.76B). The key difference: Medpace Holdings Inc is far larger — about 4.5× Workiva Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | WK | |
|---|---|---|
Market Cap | $16.90B | $3.76B |
Sector | Technology | Technology |
52-Week High | $620.59 | $93.31 |
52-Week Low | $393.42 | $44.31 |
Enterprise Value | $16.52B | $3.73B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Workiva (WK) trades at $67.62, up 0.45% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and revenue growth accelerating to 19% in Q2 2026. Technical indicators signal bullish momentum despite overbought RSI conditions, while fundamentals reflect improving profitability with net income margin turning positive to 4.87% in 2026.
Outlook remains positive with 89% analyst buy ratings and $69 consensus target offering 2% upside. Key opportunities include AI product expansion and sustained subscription growth, while risks involve high valuation multiples (P/E 82.2) and competitive pressures in regulatory software. The stock's proximity to 52-week highs suggests momentum but warrants caution on pullbacks.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →